PDLLA+HA Composite Gel
Poly-DL-Lactide Microspheres Composite Gel
(Soft Regenerative Composite Substrate Raw Material)
Product Overview
PDLLA+HA composite system is composed of amorphous PDLLA (Poly-DL-Lactide) microspheres compounded with high-purity hyaluronic acid gel. It combines the mild regenerative property of PDLLA and the instant moisturizing & supporting advantages of hyaluronic acid. Featuring moderate degradation rate and smooth, soft texture, the formula avoids the dryness issue of single microsphere powder.
It serves as a classic composite substrate for improving mid-face soft tissue volume loss, soft tissue depression and rough dry skin, mainly applied in the formula development of compound minimally invasive aesthetic repair and anti-aging finished products.
Core Customizable Technology
Adjustable particle size: Built-in PDLLA microspheres support full specification customization from 10–100 μm; 20–50 μm is the universal size suitable for multi-layer soft tissue repair formulas.
Adjustable degradation cycle: The degradation rate is controlled via amorphous molecular structure of PDLLA to achieve medium-speed sustained release, balancing instant plumping effect and long-term collagen stimulation.
Adjustable compound ratio: The proportion of PDLLA microspheres and hyaluronic acid can be customized on demand. The system is also compatible with additional active raw materials such as recombinant collagen and PDRN to enrich finished product portfolios.
Optimized dispersion system: Microspheres disperse evenly in HA gel without sedimentation and agglomeration, eliminating complicated homogenization procedures and simplifying downstream preparation processing.
Adjustable gel matrix: The viscoelasticity and transparency of HA gel can be modified to fit different application solutions including superficial care and mesotherapy delivery.
Mechanism of Action
Within the composite system, hyaluronic acid gel quickly fills gaps in soft tissues, instantly relieves dryness and fine lines, and delivers smooth application experience. Amorphous PDLLA microspheres undergo slow and steady hydrolysis with mild metabolic process and low irritation, unlikely to trigger severe inflammatory response. The microspheres continuously and gently activate fibroblasts and induce balanced autologous collagen regeneration.
The system delivers instant moisturizing and brightening effect as well as immediate depression smoothing, together with long-term soft tissue volume restoration. It ameliorates malar volume loss, nasolabial fold depression and dull rough skin, achieving natural and soft soft tissue condition after application.
Core Advantages
Synergistic soft & rigid system: HA offers instant hydration and support, while PDLLA enables long-term collagen regeneration, balancing immediate benefits and sustained repair.
Excellent biocompatibility: Mild degradation reaction, suitable for sensitive superficial soft tissues and mid-face applications.
Flexible customizable parameters: Microsphere particle size, degradation cycle, solid content ratio and matrix viscosity are all adjustable. One raw material supports the development of multiple finished product lines.
Strong compatibility: Capable of compounding with various bioactive materials, reducing formulation testing and R&D costs for brands.
High-purity raw material standard: Production criteria refer to implant-grade biomaterials, with physical and chemical indicators meeting compliance requirements for medical device raw materials.
Application Scenarios
OEM & Brand Manufacturing: PDLLA composite regenerative gel raw materials, gentle anti-aging mesotherapy raw materials, composite substrates for regenerative repair preparation OEM;
Aesthetic Clinic Supporting Materials: Volume restoration for malar area and nasolabial folds, superficial sensitive skin anti-aging care, supporting raw materials for mesotherapy collagen maintenance programs;
Distribution Supply: Sample raw materials for aesthetic institutions, formula development raw materials for skincare & minimally invasive aesthetic brands, raw material cooperation for regenerative finished products at home and overseas.
Disclaimer
Our company only develops and sells medical biological raw materials, and does not manufacture or sell finished medical device products. Customers shall independently complete the R&D, processing, registration and filing of finished products after purchasing raw materials. Finished products can only be launched into the market after obtaining corresponding compliance qualifications. This document only objectively describes the physical and chemical properties of raw materials and shall not constitute any efficacy commitment for finished products.